Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 86 clinical trials
CD22 Redirected Autologous T Cells for ALL

chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART22" cells) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic

cancer chemotherapy
lymphocytic leukemia
tyrosine
leukemia
central nervous system disease
  • 5 views
  • 25 Mar, 2022
  • 1 location
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will

methotrexate
dexamethasone
combination chemotherapy
mercaptopurine
lymphoid leukemia
  • 0 views
  • 15 Mar, 2022
  • 105 locations
Natural Killer (NK) Cell Therapy for B-Cell Malignancies

This is an open-label, Phase I study of QN-019a (allogeneic CAR-NK cells targeting CD19) as monotherapy in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and in combination with

  • 0 views
  • 31 May, 2022
  • 1 location
Study of Out of Specification for Tisagenlecleucel

tisagenlecleucel in pediatric/young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (pALL) and adult patients with r/r large B-cell lymphoma (LBCL) including diffuse large B-cell

leukemia
leukapheresis
lymphoma
follicular lymphoma
b-cell lymphoma
  • 4 views
  • 05 Jun, 2022
  • 27 locations
ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia

gilbert's syndrome
philadelphia chromosome
prednisone
male sterilization
dasatinib
  • 10 views
  • 15 Feb, 2022
  • 6 locations
Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL

This is a phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This study

b-cell acute lymphoblastic leukemia
minimal residual disease
residual tumor
cell transplantation
lymphoid leukemia
  • 2 views
  • 26 Feb, 2022
  • 1 location
Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

The patients with relapsed B cell acute lymphoblastic leukemia (ALL) after hematopoietic stem cell transplant (HSCT) have a poor prognosis, especially for these relapsed in a short time after

b-cell acute lymphoblastic leukemia
cell transplantation
stem cell transplantation
lymphoid leukemia
cancer
  • 0 views
  • 26 Jan, 2021
  • 1 location
Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-CD123 in patients with hematologic and lymphatic malignancies positive for CD123 marker. The UniCAR02-T-CD123 drug is a combination of a cellular …

refractory acute myeloid leukemia (aml)
ejection fraction
fludarabine
cyclophosphamide
blast cells
  • 19 views
  • 23 Mar, 2022
  • 6 locations
CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML

B-cell surface antigen CD19, following administration of lymphodepleting chemotherapy regimen, in children and adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B- ALL) or

  • 0 views
  • 02 Apr, 2021
  • 1 location
First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS)

This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.

  • 0 views
  • 24 May, 2022
  • 4 locations